Patients with NVAF or VTE: Practical considerations for transitioning from warfarin to a DOAC
NHS England has recently published a clinical guide for the management of anticoagulant services during the COVID 19 Pandemic1. The clinical guide states transitioning appropriate patients from warfarin to a DOAC may be considered to avoid regular blood test for INR monitoring.
To ensure non-valvular Atrial Fibrillation and Venous Thromboembolism (DVT/PE) patients who are currently receiving warfarin follow the NHS England guidance1 in response to the pandemic, Bayer have developed a slide set which provides clear information to support you and your patients during this difficult time.
To access this information, please click the button below.
In conjunction with MediConf, this educational resource has been developed and fully funded by Bayer and will contain promotional content.
1. Royal Pharmaceutical Society www.rpharms.com Accessed 30 March 2020.
We are regularly updating our website with new resources to support you and your patients. Please click here to subscribe to receive electronic communications about Bayer’s products, services and events.
Reporting adverse events and quality complaints
This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc.
If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 0118 206 3500 or Email: firstname.lastname@example.org
Further information is available on the "contact" tab at www.bayer.co.uk.